Availability by country, dated, with primary sources — one year on

Availability by country, dated, with primary sources — one year on — setting out what I have, and where I think it stops being reliable.

Documenting an access outcome, dated, because everything in this category expires.

As of January 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

post #7 answers the question as asked. The question underneath it is different.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

I read post #10 twice before replying, because I had assumed the opposite.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.